Veradermics ayaa dhammaystirtay diiwaangelinta ka-qaybgalayaasha tijaabadeeda labaad ee muhiimka ah ee Wejiga III (Phase III) ee daawada VDPHL01, oo loogu talagalay daaweynta timaha ka daata ee ragga (male pattern hair loss).
Tijaabada ‘304’ ee Wejiga III waa mid kala-sooc ah (randomised), ka socota xarumo badan (multi-centre), lagu barbardhigayo daawo madhan (placebo-controlled), isla markaana laba-indhood la’ (double-blind). Waxay qiimeynaysaa waxtarka iyo badbaadada VDPHL01 iyadoo lagu tijaabinayo 536 rag ah oo qaba timo-daadis heer fudud ilaa dhexdhexaad ah.
Ka-qaybgalayaashu waxay qaadan doonaan 8.5mg hal mar maalintii ama laba jeer maalintii muddo 52 toddobaad ah. Yoolalka ugu waaweyn (co-primary endpoints) waxaa ka mid ah:
- Isbeddelka tirada timaha aan ahayn vellus (timo dhuuban oo jilicsan),
- Iyo hagaagga daboolidda timaha sida ay bukaannadu sheegeen 24 toddobaad gudahood.
Tallaabadan kadib, shirkaddu waxay hadda dhammaystirtay diiwaangelinta labadeeda tijaabo ee Wejiga III ee VDPHL01 ee ragga, kuwaas oo ay ku lug leeyihiin in ka badan 1,000 ka-qaybgale.
VDPHL01 waa nooc kiniin afka laga qaato oo sii-dayn tartiib ah (extended-release) oo laga sameeyay minoxidil, loona horumariyay in la xoojiyo dib-u-koritaanka timaha iyadoo la yareynayo waxyeellada wadnaha la xiriirta. Qaabkan sii-daynta tartiibta ah wuxuu adeegsadaa jel si uu u bixiyo minoxidil si deggan oo muddo dheer ah, taas oo loogu talagalay inay taageerto koritaan degdeg ah oo joogto ah oo timaha ah iyada oo aan la keenin koror kedis ah oo ku yimaada heerarka daawada ee dhiigga (taas oo sababi karta dhibaatooyin wadne).
Tijaabadii hore ee Wejiga II/III ee ragga ayaa dhammaystirtay diiwaangelinta sannadka 2025, waxaana la filayaa in natiijooyinka hordhaca ah la shaaciyo qeybta hore ee 2026. Xog hordhac ah oo laga helay tijaabo kale oo Wejiga II ah oo sannadkii hore la shaaciyay ayaa muujisay koritaan timo oo la arki karo lana cabbiri karo kadib isticmaalka VDPHL01.
Shirkaddu waxay sidoo kale hadda diiwaangelinaysaa ka-qaybgalayaal dumar ah oo loogu talagalay tijaabadeeda Wejiga II/III ee ku saabsan timo-daadiska dumarka.
Maamulaha guud ee Veradermics, Reid Waldman, ayaa yiri: “Dhammaystirka diiwaangelinta labada tijaabo ee Wejiga III ee ragga waa guul muhiim ah oo u soo hoyatay Veradermics iyo tallaabo weyn oo horumarinta VDPHL01 ah.
“Guushan waxay ka tarjumaysaa dadaalka cilmi-baarayaasha, ka-qaybgalayaasha, iyo kooxaha caafimaad ee suurageliyay barnaamij adag oo loogu talagalay oggolaansho diiwaangelin (registration-directed programme) xaalad muddo tobanaan sano ah aan helin hal-abuurnimo daawo oo badan. Iyadoo diiwaangelinta ragga hadda la dhammaystiray, waxaan u sii soconnaa gudbinta codsigeennii ugu horreeyay ee NDA (New Drug Application) ee daawo afka laga qaato oo loogu talagalay timo-daadiska ku dhowaad 30 sano.”
Warbixintan “Veradermics concludes enrolment in second Phase III VDPHL01 trial” waxaa markii hore diyaarisay oo daabacday Hospital Management.